asimicin | 157966-79-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: asimicin
• 英文别名: rolliniastatin-1；rolliniastatin-2；4-[2,13-dihydroxy-13-[5-[5-(1-hydroxyundecyl)oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2H-furan-5-one
• CAS: 157966-79-5
• 化学式: C₃₇H₆₆O₇
• 分子量: 622.927
• InChiKey: MBABCNBNDNGODA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.7
• 重原子数：
  44
• 可旋转键数：
  25
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  asimicin 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 15.0h， 以76 mg的产率得到dihydrorolliniastatin-1
  参考文献：
  名称：

  Duret, Philippe; Laurens, Alain; Hocquemiller, Reynald, Heterocycles, 1994, vol. 39, # 2, p. 741 - 750

  摘要：

  DOI：

文献信息

• MULTIFUNCTIONAL SMALL MOLECULES
  申请人：Baker, JR. James R.

  公开号：US20120259114A1

  公开（公告）日：2012-10-11

  The present invention relates to dendrimer synthesis. Specifically, the present invention relates to triazine scaffolds capable of click chemistry for one-step synthesis of functionalized dendrimers, and methods of making and using the same.

  本发明涉及树枝状大分子的合成。具体而言，本发明涉及能够进行点击化学的 三嗪支架，用于一步法合成功能化树枝状大分子，以及制造和使用该支架的方法。
• Preparation of 4-substituted-2-buten-4-olides from mucohalic acids
  申请人：Angell Paul

  公开号：US20060004211A1

  公开（公告）日：2006-01-05

  Methods and materials for preparing 4-substituted-2-buten-4-olides are disclosed. The method includes reacting a mucohalic acid with a silyl enol ether or a ketene silyl acetal in the presence of a Lewis acid.

  披露了制备4-取代-2-丁烯-4-内酯的方法和材料。该方法包括将一个粘酸与一个硅基烯醇醚或一个硅基酮缩酮在路易斯酸的存在的条件下进行反应。
• [EN] METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS<br/>[FR] MÉTHODES ET COMPOSITIONS PERMETTANT DE TRAITER DES MALADIES ET AFFECTIONS À MÉDIATION PAR RHO/MRTF
  申请人：UNIV MICHIGAN

  公开号：WO2015138326A1

  公开（公告）日：2015-09-17

  The present disclosure relates to methods, compositions, and kits for the inhibition of signaling by members of the Rho GTPase family. Specifically, the disclosure relates to methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signaling and action os the transcripton co-factors MRTF-A and/or MRTF-B. The disclosure finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis and fibrosis), Rho-mediated biological conditions, and in cell signaling research.

  本公开涉及抑制Rho GTPase家族成员信号传导的方法、组合物和试剂盒。具体而言，本公开涉及用于抑制RhoA和/或RhoC转录信号传导以及转录共因子MRTF-A和/或MRTF-B的作用的方法、组合物和试剂盒。该公开揭示在治疗Rho介导的疾病状态（如肿瘤转移和纤维化）、Rho介导的生物条件和细胞信号研究中的用途。
• METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20150250769A1

  公开（公告）日：2015-09-10

  The present disclosure relates to methods, compositions, and kits for the inhibition of signaling by members of the Rho GTPase family. Specifically, the disclosure relates to methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signaling and action of the transcription co-factors MRTF-A and/or MRTF-B. The disclosure finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis and fibrosis), Rho-mediated biological conditions, and in cell signaling research.

  本公开涉及用于抑制Rho GTPase家族成员信号传导的方法、组合物和试剂盒。具体而言，本公开涉及用于抑制RhoA和/或RhoC转录信号传导以及转录共因子MRTF-A和/或MRTF-B作用的方法、组合物和试剂盒。本公开适用于治疗Rho介导的疾病状态（例如肿瘤转移和纤维化）、Rho介导的生物条件以及细胞信号研究。
• [EN] THERAPY FOR MALIGNANT DISEASE<br/>[FR] THÉRAPIE POUR UNE AFFECTION MALIGNE
  申请人：WOMAN & INFANTS' HOSPITAL OF RHODE ISLAND

  公开号：WO2016154629A1

  公开（公告）日：2016-09-29

  Provided herein, inter alia, are methods and compositions directed to suppressing tumor cell growth in a subject as well as methods for sensitizing a proliferating cell for treatment with a cytotoxic agent via inhibiting expression of HE4 and one or more immune checkpoint inhibitors (ICIs). Also provided herein are methods for determining whether a subject who has been diagnosed with cancer would benefit from immunotherapy as well as methods for determining whether a subject with cancer is responding to immunotherapy via assessment of levels of HE4 gene and/or protein expression.

  本文提供了用于抑制肿瘤细胞在受试者中生长的方法和组合物，以及用于通过抑制HE4和一个或多个免疫检查点抑制剂（ICI）的表达来使增殖细胞对细胞毒性药物治疗敏感的方法。还提供了用于确定已被诊断患有癌症的受试者是否会从免疫疗法中受益的方法，以及通过评估HE4基因和/或蛋白质表达水平来确定癌症受试者是否对免疫疗法做出反应的方法。